The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
A Review of Buprenorphine Diversion and Misuse: The Current Evidence Base and Experiences From Around the World
Open accessAbstract
Outpatient opioid addiction treatment with sublingual buprenorphine pharmacotherapy has rapidly expanded in the United States and abroad, and, with this increase in medication availability, there have been increasing concerns about its diversion, misuse, and related harms. This narrative review defines the behaviors of diversion and misuse, examines how the pharmacology of buprenorphine alone and in combination with naloxone influence its abuse liability, and describes the epidemiological data on buprenorphine diversion and intravenous misuse, risk factors for its intravenous misuse, and the unintended consequences of misuse and diversion. Physician practices to prevent, screen for, and therapeutically respond to these behaviors, which are a form of medication nonadherence, are discussed, and gaps in knowledge are identified. Outpatient opioid addiction treatment with sublingual buprenorphine pharmacotherapy experiences from other countries that have varied health care systems, public policies, and access to addiction treatment are shared to make clear that diversion and misuse occur across the world in various contexts, for many different reasons, and are not limited to buprenorphine. Comparisons are made with other opioids with known abuse liability and medications with no known abuse. The objective was to facilitate understanding of diversion and misuse so that all factors influencing their expression (patient and provider characteristics and public policy) can be appreciated within a framework that also recognizes the benefits of addiction treatment. With this comprehensive perspective, further careful work can help determine how to minimize these behaviors without eroding the current benefits realized through improved addiction treatment access and expansion.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drug Dependence, a Chronic Medical Illness
McLellan, A. T., Lewis, D. C., O'Brien, C. P., & Kleber, H. D. (2000) · JAMA · doi:10.1001/jama.284.13.1689 · Cited by 2,622 · cited 1×
“A punitive “no tolerance” approach with automatic discharge from treatment is highly unlikely to help patients, because untreated opioid addiction is characterized by relapse (continued use of illicit [ie, diverted] opioids is the norm) and increased morbidity and mortality (McLellan et al., 2000).”
BackgroundClinical pharmacology of buprenorphine: Ceiling effects at high doses
Walsh, S. L., Preston, K. L., Stitzer, M. L., Cone, E. J., & Bigelow, G. E. (1994) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1994.71 · Cited by 773
Self-citationEffective Medical Treatment of Opiate Addiction
Addiction, N. C. D. P. O. E. M. T. O. O. (1998) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.280.22.1936 · Cited by 577
Counseling plus Buprenorphine–Naloxone Maintenance Therapy for Opioid Dependence
Fiellin, D. A., Pantalon, M. V., Chawarski, M. C., Moore, B. A., Sullivan, L. E., O'Connor, P. G., & Schottenfeld, R. S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055255 · Cited by 351
Opioid agonist treatments and heroin overdose deaths in Baltimore, Maryland, 1995–2009
Schwartz, R. P., Gryczynski, J., O’Grady, K. E., Sharfstein, J. M., Warren, G., Olsen, Y., Mitchell, S. G., & Jaffe, J. H. (2013) · American Journal of Public Health · doi:10.2105/ajph.2012.301049 · Cited by 276
Middleton, L. S., Nuzzo, P. A., Lofwall, M. R., Moody, D. E., & Walsh, S. L. (2011) · Addiction · doi:10.1111/j.1360-0443.2011.03424.x · Cited by 77
Self-citationVignau, J., Duhamel, A., Catteau, J., Legal, G., Huynh, A., Grailles, I., Beauvillain, J., Petit, P., Beauvillain, P., & Parquet, P. J. (2001) · Journal of Substance Abuse Treatment · doi:10.1016/s0740-5472(01)00189-1 · Cited by 39
Cited by
The changing opioid crisis: development, challenges and opportunities
Volkow, N. D., & Blanco, C. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-0661-4 · Cited by 522
Management of opioid use disorders: a national clinical practice guideline
Bruneau, J., Ahamad, K., Goyer, M.-È., Poulin, G., Selby, P., Fischer, B., Wild, T. C., & Wood, E. (2018) · Canadian Medical Association Journal · doi:10.1503/cmaj.170958 · Cited by 412
Management of opioid use disorder in the USA: present status and future directions
Blanco, C., & Volkow, N. D. (2019) · The Lancet · doi:10.1016/s0140-6736(18)33078-2 · Cited by 407
Lofwall, M. R., Walsh, S. L., Nunes, E. V., Bailey, G. L., Sigmon, S. C., Kampman, K. M., Frost, M., Tiberg, F., Linden, M., Sheldon, B., et al. (2018) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2018.1052 · Cited by 255
Self-citationThe Next Stage of Buprenorphine Care for Opioid Use Disorder
Martin, S. A., Chiodo, L. M., Bosse, J. D., & Wilson, A. (2018) · Annals of Internal Medicine · doi:10.7326/m18-1652 · Cited by 130
Metadata
- Authors
- Lofwall, M. R., & Walsh, S. L.
- Venue
- Journal of Addiction Medicine
- Published
- 2014-09
- Volume
- 8
- Issue
- 5
- Pages
- 315-326
- ISSN
- 1932-0620 (ISSN-L)
- OpenAlex
- W1997040233
- Cited by
- 248
- References
- 7
- FWCI
- 12.26
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Review of Buprenorphine Diversion and Misuse: The Current Evidence Base and Experiences From Around the World. https://app.cochat.ai/papers/10.1097/adm.0000000000000045
- The paper
- Lofwall, M. R., & Walsh, S. L. (2014). A Review of Buprenorphine Diversion and Misuse: The Current Evidence Base and Experiences From Around the World. Journal of Addiction Medicine. https://doi.org/10.1097/adm.0000000000000045
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.